COMP <GO>
BMY vs ABT // EV/EBITDA & P/E VALUATION
Bristol-Myers Squibb Company (NYSE) VS. Abbott Laboratories (NYSE) • 15-METRIC TALLY: BMY 6
— ABT 8
▲ EV/EBITDA & P/E VALUATION LEADER: BMY
LAST: $62.48 (+1.78%) • MKT CAP: $125.40B
valuation
16.3x
LAST: $106.20 (+1.56%) • MKT CAP: $180.95B
valuation
18.4x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BMY VS. ABT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BMY | ABT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 71.10% | 56.40% | +14.70 | BMY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 13.30% | 11.90% | +1.40 | BMY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 16.3x | 18.4x | -2.10 | BMY | /valuation <GO> |
| Free Cash Flow Yield | 10.24% | 4.09% | +6.15 | BMY | /fcf-yield <GO> |
| Operating Margin | 17.90% | 18.20% | -0.30 | ABT | /operating-margins <GO> |
| Net Profit Margin | 14.60% | 14.70% | -0.10 | ABT | /net-margins <GO> |
| Revenue Growth (YoY) | -0.20% | 5.70% | -5.90 | ABT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 4.02% | 2.27% | +1.75 | BMY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.24 | 4.36 | -2.12 | ABT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | ABT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.4 | 54.2 | -3.80 | ABT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 0.99 | -0.01 | ABT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 16.6x | 25.8x | -9.20 | BMY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $125.40B | $180.95B | -$55.54B | ABT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BMY REV | ABT REV | BMY GROSS % | ABT GROSS % | BMY FCF | ABT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $48.19B | $44.33B | 71.1% | 56.4% | $12.85B | $7.39B |
| FY 2024 | $48.30B | $41.95B | 71.1% | 55.4% | $13.94B | $6.35B |
| FY 2023 | $45.01B | $40.11B | — | — | $11.83B | $5.46B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BMY // BETA 0.98
ABT // BETA 0.99